ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist

被引:4
作者
Acuña-Castillo, C
Scorza, C
Reyes-Parada, M
Cassels, BK
Huidobro-Toro, JP
机构
[1] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Fisiol,Ctr Regulac Celular & Patol, Inst Milenio Biol Fundamental & Aplicada, Santiago 1, Chile
[2] Inst Invest Biol Clemente Estable, Div Biol Celular, Montevideo, Uruguay
[3] Univ Santiago Chile, Fac Ciencias Med, Santiago, Chile
[4] Univ Chile, Fac Ciencias, Dept Quim, Inst Milenio Estudios Avanzados Biol Celular & Bi, Santiago, Chile
关键词
ALEPH-2; 5-hydroxytryptamine; 5-HT2A and 5-HT2C receptors; phenylisopropylamine derivatives;
D O I
10.1016/S0024-3205(00)00906-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
To assess the pharmacodynamic profile of ALEPH-2, a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties,Xenopus laevis oocytes were microinjected with either of the rat cRNA for the 5-HT2A or the 5-HT2C receptor. Concentration-response curves were obtained following the exposure of the oocytes to varying concentrations of either ALEPH-2 or 5-hydroxy-tryptamine (5-HT) for 10 s. ALEPH-2 is a partial agonist on the 5-HT,,receptor with a similar potency to 5-HT. In contrast, ALEPH-2 is a full 5-HT2C receptor agonist and is about 15-fold less potent than 5-HT. Pre-application of 1 muM ritanserin antagonized the responses induced by 5-HT and ALEPH-2 to the same extent; however, the 5-HT2A receptor is more sensitive to ritanserin blockade than the 5-HT2C receptor. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:3241 / 3247
页数:7
相关论文
共 50 条
  • [21] Further pharmacological characterization of 5-HT2C receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo
    Queree, P.
    Peters, S.
    Sharp, T.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (06) : 1477 - 1485
  • [22] The 5-HT2C/2B receptor agonist, m-chlorophenylpiperazine, increases plasma glucagon levels in rats
    Yamada, J
    Sugimoto, Y
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) : 153 - 157
  • [23] Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders
    Wood, Martyn D.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (06) : 383 - 387
  • [24] Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist
    Kimura, Y
    Hatanaka, K
    Naitou, Y
    Maeno, K
    Shimada, I
    Koakutsu, A
    Wanibuchi, F
    Yamaguchi, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 483 (01) : 37 - 43
  • [25] 5-HT7 Receptor Restrains 5-HT-induced 5-HT2A Mediated Contraction in the Isolated Abdominal Vena Cava
    Gonzalez-Pons, Romina
    McRae, Kiera
    Thompson, Janice M.
    Watts, Stephanie W.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (02) : 319 - 327
  • [26] Serotonin and drug reward:: focus on 5-HT2C receptors
    Higgins, GA
    Fletcher, PJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 480 (1-3) : 151 - 162
  • [27] Mesenteric vasoconstrictor response to 5-hydroxytryptamine in the in situ blood autoperfused rat mesentery:: involvement of 5-HT2B and/or 5-HT2C receptor activation
    Fernández, MD
    Morán, A
    Martín, ML
    San Román, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (02) : 221 - 227
  • [28] Serotonin (5-HT) and 5-HT2A receptor agonists suppress lipolysis in primary rat adipose cells
    Hansson, Bjorn
    Medina, Anya
    Fryklund, Claes
    Fex, Malin
    Stenkula, Karin G.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (02) : 357 - 363
  • [29] REPEATED COCAINE MODIFIES THE NEUROENDOCRINE RESPONSES TO THE 5-HT(1C) 5-HT(2)-RECEPTOR AGONIST DOI
    LEVY, AD
    LI, Q
    SANZ, MCA
    RITTENHOUSE, PA
    BROWNFIELD, MS
    VANDEKAR, LD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 221 (01) : 121 - 127
  • [30] In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism
    Boothman, L.
    Raley, J.
    Denk, F.
    Hirani, E.
    Sharp, T.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (07) : 861 - 869